Clinical Trial Update: Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo [Phase 3]

View source ↗

Summary

A Phase 3 trial update for SB-275833 ointment 1% for impetigo (a bacterial skin infection) is reported as completed, under GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo

Drugs mentioned

• SB-275833 ointment (SB-275833)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Skin Infections, Bacterial | Phase 3 | Status: COMPLETED